Comparable stake leader
Of Joseph Feldschuh Estate
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000027367.
Comparable stake leader
Of Joseph Feldschuh Estate
Disclosed value leader
Of Joseph Feldschuh Estate
Comparable rows
0/24
Latest evidence
08 Apr 2026
Ownership snapshot
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Quick read
0 of 24 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Of Joseph Feldschuh Estate |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$24,857,186
2,549,455 shares
|
— | 18 Sep 2023 |
| THOMPSON SIEGEL & WALMSLEY LLC |
13F
Company
|
—
class O/S missing
|
$2,245,000
232,120 shares
|
— | 31 Mar 2026 |
| Michael Richard Feldschuh |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
$1,938,204
213,694 shares
|
+$9,070 | 08 Apr 2026 |
| Jonathan Adam Feldschuh |
3/4/5
Chief Scientific Officer, Director
|
—
class O/S missing
|
$691,639
53,908 shares
|
— | 09 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$469,282
48,280 shares
|
— | 31 Mar 2026 |
| Aristides Capital LLC |
13F
Company
|
—
class O/S missing
|
$403,162
41,692 shares
|
— | 31 Mar 2026 |
| John Jefferies |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$347,465
23,557 shares
|
— | 20 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
class O/S missing
|
$270,866
28,011 shares
|
— | 31 Mar 2026 |
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Net insider flow leans to buying over the last 12 months. Net value: +$18,970.
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 2,000 | 0 | $18,970 | $0 | +$18,970 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Showing 1-10 of 10 reporting-owner rows connected to DAXOR CORP. Open a relationship link for the CIK-to-CIK filing trail.
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Of Joseph Feldschuh Estate | 10%+ Owner | $24,857,186 | Mixed | 18 Sep 2023 | ||
| Michael Richard Feldschuh | Chief Executive Officer, Director | $1,938,204 | +$9,070 | +0.47% | Filing P/S | 08 Apr 2026 |
| Jonathan Adam Feldschuh | Chief Scientific Officer, Director | $691,639 | Mixed | 09 Dec 2025 | ||
| John Jefferies | Chief Medical Officer | $347,465 | Mixed | 20 Mar 2026 | ||
| Robert J. Michel | Chief Financial Officer | $208,395 | +$9,900 | +5% | Filing P/S | 31 Mar 2026 |
| Caleb DesRosiers | Director | Mixed | 24 Jun 2025 | |||
| James A. Lombard | Director | Mixed | 11 Jul 2023 | |||
| Henry D. Cremisi | Director | Mixed | 24 Jun 2025 | |||
| Joy S. Goudie | Director | Mixed | 24 Jun 2025 | |||
| Edward Feuer | Director | Mixed | 24 Jun 2025 |
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Richard Feldschuh | DXR | Daxor Common Stock | Purchase | 0.47% | $9,070 | $9.07 | 1,000 | 213,694 | 08 Apr 2026 | Direct |
| Robert J. Michel | DXR | Daxor Common Stock | Purchase | 4.99% | $9,900 | $9.90 | 1,000 | 21,050 | 31 Mar 2026 | Direct |
| John Jefferies | DXR | Daxor Common Stock | Purchase | 33.7% | 5,941 | 23,557 | 20 Mar 2026 | Direct | ||
| Robert J. Michel | DXR | Daxor Common Stock | Purchase | 17.6% | 3,000 | 20,050 | 09 Dec 2025 | Direct | ||
| Jonathan Adam Feldschuh | DXR | Daxor Common Stock | Purchase | 50.1% | 18,000 | 53,908 | 09 Dec 2025 | Direct | ||
| John Jefferies | DXR | Daxor Common Stock | Purchase | 15.4% | 2,344 | 17,616 | 12 Nov 2025 | Direct | ||
| Henry D. Cremisi | DXR | Stock Options (right to buy) | Award | 2,500 | 2,500 | 24 Jun 2025 | Direct | |||
| Edward Feuer | DXR | Stock Options (right to buy) | Award | 2,500 | 2,500 | 24 Jun 2025 | Direct | |||
| Joy S. Goudie | DXR | Stock Options (right to buy) | Award | 2,500 | 2,500 | 24 Jun 2025 | Direct | |||
| Caleb DesRosiers | DXR | Stock options (right to buy) | Award | 2,500 | 2,500 | 24 Jun 2025 | Direct |